Zynex (ZYXI) 10-Q 7 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 04, 2014
Document And Entity Information [Abstract]	'	'
Entity Registrant Name	'ZYNEX INC	'
Entity Central Index Key	'0000846475	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-14	'
Amendment Flag	'false	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	31,271,234

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current Assets:	'	'
Cash	$319	$323
Accounts receivable, net	4,460	7,033
Inventory, net	2,483	5,002
Prepaid expenses	37	346
Deferred tax assets, net	72	72
Income tax receivable	219	893
Other current assets	'	35
Total current assets	7,590	13,704
Property and equipment, net	1,833	2,891
Deposits	3	400
Deferred financing fees, net	'	48
Intangible assets, net	142	178
Total assets	9,568	17,221
Current Liabilities:	'	'
Line of credit	4,541	5,820
Current portion of notes payable and other obligations	82	92
Accounts payable	2,745	2,743
Income taxes payable	78	96
Accrued payroll and payroll taxes	654	607
Current portion of contingent consideration	4	7
Deferred revenue	109	0
Other accrued liabilities	137	319
Total current liabilities	8,350	9,684
Notes payable and other obligations, less current portion	78	150
Deferred rent	2,845	2,454
Deferred tax liabilities, net	72	72
Warranty liability	12	13
Total liabilities	11,357	12,373
Stockholders’ (Deficit) Equity:	'	'
Preferred stock; $.001 par value, 10,000,000 shares authorized, no shares issued or outstanding	'	'
Common stock, $.001 par value, 100,000,000 shares authorized, 31,271,234 (2014) and 31,171,234 (2013) shares issued and outstanding	31	31
Paid-in capital	5,683	5,586
Accumulated deficit	-7,459	-735
Total Zynex, Inc. stockholders’ (deficit) equity	-1,745	4,882
Noncontrolling interest	-44	-34
Total stockholders’ (deficit) equity	-1,789	4,848
Total liabilities and stockholders’ (deficit) equity	$9,568	$17,221

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Statement Of Financial Position [Abstract]	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	'	'
Preferred stock, shares outstanding	'	'
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	31,271,234	31,171,234
Common stock, shares outstanding	31,271,234	31,171,234

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Net revenue:	'	'	'	'
Rental	$389	$1,284	$1,713	$4,606
Sales	4,015	3,907	7,208	13,725
Total net revenue	4,404	5,191	8,921	18,331
Operating expenses:	'	'	'	'
Cost of revenue - rental	172	257	575	956
Cost of revenue - sales	1,211	1,289	2,976	4,664
Cost of revenue - write-off of noncore inventory	'	'	2,655	'
Selling, general and administrative expense	2,609	4,713	9,012	16,699
Income (loss) from operations	412	-1,068	-6,297	-3,988
Other income (expense):	'	'	'	'
Interest expense	-169	-136	-471	-480
Other income	25	'	34	72
Total other income (expense)	-144	-136	-437	-408
Income (loss) before income taxes	268	-1,204	-6,734	-4,396
Income tax benefit	'	455	'	1,610
Net income (loss)	268	-749	-6,734	-2,786
Plus: Net (income) loss – noncontrolling interest	-10	11	10	28
Net income (loss) – attributable to Zynex, Inc.	$258	($738)	($6,724)	($2,758)
Net income (loss) per share – attributable to Zynex, Inc.	'	'	'	'
Basic	$0.01	($0.02)	($0.22)	($0.09)
Diluted	$0.01	($0.02)	($0.22)	($0.09)
Weighted - average number of common shares outstanding:	'	'	'	'
Basic	31,215,799	31,148,234	31,186,252	31,148,234
Diluted	31,215,799	31,148,234	31,186,252	31,148,234

Condensed_Consolidated_Stateme1

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (USD $)	Total	Common Stock	Paid-in Capital	Retained Deficit	Noncontrolling Interest
In Thousands, except Share data
Balance at Dec. 31, 2013	$4,848	$31	$5,586	($735)	($34)
Balance, shares at Dec. 31, 2013	31,171,234	31,171,234	'	'	'
Employee stock-based compensation expense	74	'	74	'	'
Shares issued for services	'	100,000	'	'	'
Value, Issued for Services	23	'	23	'	'
Net loss	-6,734	'	'	-6,724	-10
Balance at Sep. 30, 2014	($1,789)	$31	$5,683	($7,459)	($44)
Balance, shares at Sep. 30, 2014	31,271,234	31,271,234	'	'	'

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:	'	'
Net loss	($6,734)	($2,786)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation expense	433	608
Warranty expense	-1	-6
Writeoff of noncore inventory	2,005	'
Write-off rental units	650	'
Change in the value of contingent consideration	'	-70
Change in provision for losses on accounts receivable	-901	442
Amortization of intangible assets	36	39
Impairment of intangible assets	'	100
Impairment of goodwill	'	39
Amortization of financing fees	48	38
Issuance of common stock for services	23	'
Change in obsolete inventory	336	293
Deferred rent	391	1,033
Employee stock-based compensation expense	74	98
Gain on asset disposal	33	-6
Changes in operating assets and liabilities:	'	'
Accounts receivable	3,474	2,959
Inventory	186	-265
Income tax receivable	674	'
Prepaid expenses	309	65
Deposits and other current assets	44	-2,057
Accounts payable	2	232
Accrued liabilities	-135	-1,048
Deferred revenue	109	'
Income taxes payable	-17	-384
Net cash provided by (used in) operating activities	1,039	-676
Cash flows from investing activities:	'	'
Sales (purchases) of equipment	216	-501
Change in inventory used for rental	106	550
Payments on contingent consideration	-4	-3
Net cash provided by investing activities	318	46
Cash flows from financing activities:	'	'
Net (repayments) borrowings on line of credit	-1,279	385
Payments on notes payable and capital lease obligations	-82	-110
Net cash (used in) provided by financing activities	-1,361	275
Net decrease in cash	-4	-355
Cash at the beginning of the period	323	823
Cash at the end of the period	319	468
Supplemental cash flow information:	'	'
Interest paid	133	449
Income taxes paid (including interest and penalties)	2	384
Supplemental disclosure of non-cash investing and financing activities:	'	'
Equipment acquired through note payable and capital lease	'	137
Deposit used to purchase equipment	$388	'

Unaudited_Condensed_Consolidat

Unaudited Condensed Consolidated Financial Statements and Managements' Plans	9 Months Ended
	Sep. 30, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
Unaudited Condensed Consolidated Financial Statements and Managements' Plans	'
	(1) UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AND MANAGEMENTS’ PLANS
	Zynex, Inc. (a Nevada corporation) and its subsidiaries, Zynex Medical, Inc. (ZMI) (a Colorado corporation, wholly-owned), Zynex NeuroDiagnostics, Inc. (ZND) (a Colorado corporation, wholly-owned), Zynex Monitoring Solutions Inc. (ZMS) (a Colorado corporation, wholly-owned), Zynex Billing and Consulting, LLC (ZBC) (a Colorado limited liability company, 80% majority-owned) and Zynex Europe, ApS (ZEU) (a Denmark corporation, wholly-owned), are collectively referred to as the “Company”.
	The unaudited condensed consolidated financial statements included herein have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and accounting principles generally accepted in the United States of America (“U.S. GAAP”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures included herein are adequate to make the information presented not misleading. A description of the Company’s accounting policies and other financial information is included in the audited consolidated financial statements as filed with the SEC in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013. Amounts as of December 31, 2013 are derived from those audited consolidated financial statements. These interim condensed consolidated financial statements should be read in conjunction with the annual audited financial statements, accounting policies and notes thereto, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, which has previously been filed with the SEC.
	In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to present fairly the financial position of the Company as of September 30, 2014 and the results of its operations and its cash flows for the periods presented.  The results of operations for the three and nine months ended September 30, 2014 are not necessarily indicative of the results that may be achieved for a full fiscal year and cannot be used to indicate financial performance for the entire year.
	The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities in the normal course of business.
	The Company reported a net loss of $6,734 for the nine months ended September 30, 2014 and $7,340 for the year ended December 31, 2013, and has no available borrowings as of September 30, 2014 under its line of credit, which had an outstanding balance of $4,541 at September 30, 2014.  As a result of the Company losses from operations, negative operating cash flow, and limited liquidity, the Company’s independent registered public accounting firm’s report on the Company’s consolidated financial statements as of and for the year ended December 31, 2013 includes an explanatory paragraph discussing that these conditions raise substantial doubt about the Company’s ability to continue as a going concern.  The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
	Over the last two years, the Company encountered industry challenges related to health care reform, including the Affordable Care Act and coverage and reimbursement changes from government and Third-party Payors (as defined below), which has caused uncertainty to exist at the medical practitioner level causing a delay and decline in demand for the Company’s ZMI electrotherapy products. In an effort to minimize the impact of health care reform and changes in reimbursement, beginning in the second quarter of 2013, the Company made reductions in its annual operating expenses by cutting the Company’s annual employee costs by approximately $7,000 through headcount reductions. In October 2014, the Company negotiated a Termination Agreement for its existing building lease and a new Lease Agreement for a reduced space at its current headquarters. Under the terms of the Termination Agreement, among other things, the Company agreed to consolidate its operations into approximately one-third of the total square footage it occupied previously; monthly base rental payments were reduced from approximately $129 to $43 for the period from September 1, 2014 through December 31, 2014; all future rental payments and deferred rent amounts will be forgiven as of December 31, 2014; and, the terms of the new lease will take effect on January 1, 2015. The terms of the new lease include, among other things, a term of two years, fixed monthly base rental payments of approximately $49 for the full term of the lease; and, the right for either party to terminate the lease without future liability upon six months written notice to the Company or three months written notice to the landlord. Refer to Note 13. Additionally, the Company recently added new products to its ZMI sales channel, including the compound and sale of topical and transdermal pain creams, which typically have more certainty as to reimbursement because all orders are preauthorized by the insurance company prior to shipment. The Company developed its operating plans for 2014 to emphasize cash flow, under which the Company is focusing on its topical pain cream sales, which the Company believes will yield high margins, streamlining the Company’s electrotherapy products sales process and continuing to implement various cost modifications to reduce the Company’s expenses.
	During the second quarter of 2014, the Company narrowed its focus to NexWave, InWave and NeuroMove electrotherapy products and continued to build the sales representative group for its TENS and compound pain cream solutions. As part of that effort, it restructured internal operations, including manufacturing, billing and customer service. As a result of these activities, the Company recorded a charge to cost of revenue – write-off of noncore inventory in the amount of $2,655, which included $2,005 of inventory and $650 of rental units in the quarter ended June 30, 2014. Refer to Note 2.
	Due to the Company’s negative cash flows, there is no guarantee that the Company will be able to meet the requirements of its 2014 operating plan.  The amount outstanding on the Company’s line of credit (the “Triumph Agreement”) decreased from $5,820 at December 31, 2013 to $4,541 at September 30, 2014, primarily driven by collection of accounts receivable. On July 14, 2014, the Company received notice from Triumph Healthcare Finance (the “Lender”) of an event of default under the Triumph Agreement. The notice relates to the Company’s default under the minimum debt service coverage ratio for the quarter ended March 31, 2014 and certain other alleged defaults. The Lender notified the Company that it was exercising its default remedies under the Triumph Agreement, including, among others, accelerating the repayment of all outstanding obligations under the Triumph Agreement (outstanding principal and accrued interest) and collecting the Company’s bank deposits to apply towards the outstanding obligations. The Company and the Lender are negotiating the terms of an accelerated repayment of the amounts outstanding under the Triumph Agreement and the Lender has continued to make additional loans to the Company under the facility. However, no assurance can be given that the Lender will continue to make such additional loans or that the parties will agree on a repayment plan acceptable to the Company. If the Lender insists upon immediate repayment, the Company will be insolvent and may be forced to seek protection from creditors.    This default under the Triumph Agreement and potential remedies the Lender can demand, raises substantial doubt about the Company’s ability to continue as a going concern. The Company’s long-term business plan contemplates organic growth in revenues, through the addition of new products to the Company’s sales channel that could add more revenue as well as growth in its ZMI electrotherapy products. Therefore, in order to support growth in revenue, the Company requires, among other things, funds for the purchase of equipment (primarily for rental inventory), funds for the purchase of inventory and the payment of commissions to sales representatives, funds for the expansion of the Company’s compound pharmacy, and the potential creation of other new product lines. There is no assurance that the Company’s operations and future access to new capital, if any, will provide enough cash for operating requirements including payment of key Company suppliers or for increases in the Company’s inventory of products, as needed, for growth.
	The Company is actively seeking external financing through the issuance of debt or sale of equity, and the Company is not certain whether any such financing would be available to the Company on acceptable terms, or at all. Any additional debt would require the approval of the Lender. The Company’s dependence on operating cash flow means that risks involved in the Company’s business can significantly affect the Company’s liquidity. Contingencies such as unanticipated shortfalls in revenues or increases in expenses could affect the Company’s projected revenues, cash flows from operations and liquidity which may force the Company to curtail its operating plan or impede the Company’s ability to grow.

Significant_Accounting_Policie

Significant Accounting Policies	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies	'
	(2) SIGNIFICANT ACCOUNTING POLICIES
	PRINCIPLES OF CONSOLIDATION
	The accompanying unaudited condensed consolidated financial statements include the accounts of Zynex, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
	NONCONTROLLING INTEREST
	Noncontrolling interest in the equity of a subsidiary is accounted for and reported as stockholders’ (deficit) equity. Noncontrolling interest represents the 20% ownership in the Company’s majority-owned subsidiary, ZBC.
	USE OF ESTIMATES
	Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The most significant management estimates used in the preparation of the accompanying condensed consolidated financial statements are associated with the allowance for contractual adjustments and uncollectible accounts receivable, the reserve for obsolete and damaged inventory, stock-based compensation, valuation of long-lived assets, and income taxes.
	REVENUE RECOGNITION, ALLOWANCE FOR CONTRACTUAL ADJUSTMENTS AND COLLECTIBILITY
	The Company recognizes revenue when each of the following four conditions are met: 1) a contract or sales arrangement exists, 2) products have been shipped and title has transferred, or rental services have been rendered, 3) the price of the products or services is fixed or determinable, and 4) collectability is reasonably assured. Accordingly, the Company recognizes revenue, both rental and sales, when products have been delivered to the patient and the patient’s insurance (if the patient has insurance) has been verified. For medical products that are sold from inventories consigned at clinic locations, the Company recognizes revenue when it receives notice that the product has been prescribed and delivered to the patient and the patient’s insurance coverage has been verified or preauthorization has been obtained from the insurance company, when required. Revenue from the rental of products is normally on a month-to-month basis and is recognized ratably over the products’ rental period. Revenue from sales to distributors is recognized when the Company ships its products, which fulfills its order and transfers title. Revenue is reported net, after adjustments for estimated insurance company or governmental agency (collectively “Third-party Payors”) reimbursement deductions. The deductions are known throughout the health care industry as “contractual adjustments” whereby the Third-party Payors unilaterally reduce the amount they reimburse for the Company’s products.
	A significant portion of the Company’s revenues are derived, and the related receivables are due, from Third-party Payors. The nature of these receivables within this industry has typically resulted in long collection cycles. The process of determining what products will be reimbursed by Third-party Payors and the amounts that they will reimburse is complex and depends on conditions and procedures that vary among providers and may change from time to time. The Company maintains an allowance for contractual adjustments and records additions to the allowance to account for the risk of nonpayment. Contractual adjustments result from reimbursements from Third-party Payors that are less than amounts claimed or where the amount claimed by the Company exceeds the Third-party Payors’ usual, customary and reasonable reimbursement rate. The Company determines the amount of the allowance, and adjusts it at the end of each reporting period, based on a number of factors, including historical rates of collection, the aging of the receivables, trends in the historical rates of collection and current relationships and experience with the Third-party Payors. If the rates of collection of past-due receivables recorded for previous fiscal periods changes, or if there is a trend in the rates of collection on those receivables, the Company may be required to change the rate at which it provides for additions to the allowance. A change in the rates of the Company’s collections can result from a number of factors, including experience and training of billing personnel, changes in the reimbursement policies or practices of Third-party Payors, or changes in industry rates of reimbursement. Accordingly, changes to the allowance for contractual adjustments, which are recorded in the income statement as a reduction of revenue, have historically fluctuated and may continue to fluctuate significantly from quarter to quarter.
	Due to the nature of the industry and the reimbursement environment in which the Company operates, estimates are required to record net revenues and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of third-party billing arrangements and the uncertainty of reimbursement amounts for certain products or services from payors or unanticipated requirements to refund payments previously received may result in adjustments to amounts originally recorded. Due to continuing changes in the health care industry and third-party reimbursement, as well as changes in our billing practices to increase cash collections, it is possible that management’s estimates could change in the near term, which could have an impact on our results of operations and cash flows. Any differences between estimated settlements and final determinations are reflected as an increase or a reduction to revenue in the period when such final determinations are known.
	The Company frequently receives refund requests from insurance providers relating to specific patients and dates of service. Billing and reimbursement disputes are very common in the Company’s industry. These requests are sometimes related to a limited number of patients or products; at other times, they include a significant number of refund claims in a single request. The Company reviews and evaluates these requests and determines if any refund request is appropriate. The Company also reviews these refund claims when it is rebilling or pursuing reimbursement from that insurance provider. The Company frequently has significant offsets against such refund requests, and sometimes amounts are due to the Company in excess of the amounts of refunds requested by the insurance providers. Therefore, at the time of receipt of such refund requests, the Company is generally unable to determine if a refund request is valid and should be accrued.
	As of September 30, 2014, the Company believes it has an adequate allowance for contractual adjustments relating to all known insurance disputes and refund requests. However, no assurances can be given with respect to such estimates of reimbursements and offsets or the ultimate outcome of any refund requests.
	In addition to the allowance for contractual adjustments, the Company records an allowance for uncollectible accounts receivable. Uncollectible accounts receivable are primarily a result of non-payment from patients who have been direct billed for co-payments or deductibles, lack of appropriate insurance coverage and disallowances of charges by Third-party Payors. If there is a change to a material insurance provider contract or policy, application by a provider, a decline in the economic condition of providers or a significant turnover of Company billing personnel resulting in diminished collection effectiveness, the estimate of the allowance for uncollectible accounts receivable may not be adequate and may result in an increase in the future. At September 30, 2014 and December 31, 2013, the allowance for uncollectible accounts receivable is $936 and $1,837, respectively.
	At September 30, 2014, the Company recorded a liability for deferred revenue in the amount of $109 which represents amounts paid by Third-party Payors for consumable supplies that were not shipped to patients as of September 30, 2014. This liability was reduced to zero in October 2014. There was no such liability at December 31, 2013.
	FAIR VALUE OF FINANCIAL INSTRUMENTS
	The Company’s financial instruments at September 30, 2014 include cash, accounts receivable and accounts payable, for which current carrying amounts approximate fair value due to their short-term nature. Financial instruments at September 30, 2014 also include the line of credit and notes payable, the carrying value of which approximates fair value because the interest rates on the outstanding borrowings are at rates that approximate market rates for borrowings with similar terms and average maturities.
	INVENTORY
	Inventories, which primarily represent finished goods, are valued at the lower of cost (average) or market. In the second quarter of 2014, the Company narrowed its focus to the NexWave, InWave and NeuroMove electrotherapy products and building the sales representative group for its TENS and compound pain cream solutions.  As a result, the Company wrote-off all inventory unrelated to those specific product lines and recorded a charge to cost of revenue – write-off of noncore inventory in the amount of $2,005 during the nine month period ended September 30, 2014. Finished goods include products held at the Company’s headquarters and at different locations by health care providers or other parties for rental or sale to patients. Total (gross) inventories at September 30, 2014 included $2,506 of finished goods, $247 of parts, and $390 of supplies.
	The Company monitors inventory for turnover and obsolescence, and records losses for excess and obsolete inventory as appropriate. The Company provides reserves for estimated excess and obsolete inventories equal to the difference between the costs of inventories on hand and the estimated market value based upon assumptions about future demand. If future demand is less favorable than currently projected by management, additional inventory write-downs may be required. To fulfill orders faster, the Company places a large amount of its inventory with field sales representatives. This increases the sensitivity of these products to obsolescence reserve estimates. As this inventory is not in the Company’s possession, management maintains additional reserves for estimated shrinkage of these inventories based on the Company’s aging. At September 30, 2014, the Company had an allowance for obsolete and damaged inventory of approximately $660. The allowance for obsolete and damaged inventory was approximately $1,278 at December 31, 2013. The decrease from December 31, 2013 is due primarily to the write-off of noncore inventory discussed above. In addition, in the second quarter of 2014, the Company changed its method of estimation for determining allowances for obsolete and damaged inventory. The Company now estimates that finished units held for sale will be reserved beginning in year three and fully reserved after four years compared to five years previously. This change in estimate had the effect of increasing the allowances for obsolete and damaged inventory by approximately $414 at September 30, 2014 and increasing cost of revenue – sales by approximately $168 ($0.01 per share) and $414 ($0.02 per share) for the three and nine months ended September 30, 2014 respectively. The Company had $107 of open purchase commitments at September 30, 2014.
	PROPERTY AND EQUIPMENT
	Property and equipment are stated at cost. Products on rental contracts are placed in property and equipment and depreciated over their estimated useful life. The Company removes the cost and the related accumulated depreciation from the accounts of assets sold or retired, and the resulting gains or losses are included in the results of operations. Depreciation is computed using the straight-line method over the useful life of the asset. As rental inventory contributes directly to the revenue generating process, the Company classifies the depreciation of rental inventory in cost of revenue. As a result of the Company’s change in product focus discussed above, the Company wrote-off all rental inventory unrelated to those specific product lines and recorded a charge to cost of revenue – write-off of noncore inventory of $650 in the second quarter of 2014.
	Repairs and maintenance costs are charged to expense as incurred.
	INTANGIBLE ASSETS
	Intangible assets with estimable lives are amortized in a pattern consistent with the asset’s identifiable cash flows or using a straight- line method over their remaining estimated benefit periods if the pattern of cash flows is not estimable. The Company reviews the carrying value of intangible and other long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by comparison of their carrying amounts to the undiscounted cash flows that the asset or asset group is expected to generate. If the carrying amount of the assets exceeds the undiscounted cash flows the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Intangible assets primarily include capitalized software. The Company capitalizes software development costs incurred during the application development stage related to new software or major enhancements to the functionality of existing software that is developed solely to meet the entity’s internal operational needs and when no substantive plans exist or are being developed to market the software externally. Costs capitalized include external direct costs of materials and services and internal payroll and payroll-related costs. Any costs during the preliminary project stage or related to training or maintenance are expensed as incurred. Capitalization ceases when the software project is substantially complete and ready for its intended use. The capitalization and ongoing assessment of recoverability of development costs requires considerable judgment by management with respect to certain external factors, including, but not limited to, technological and economic feasibility, and estimated economic life.  When the projects are ready for their intended use, the Company amortizes such costs over their estimated useful lives of five years.
	STOCK-BASED COMPENSATION
	The Company accounts for stock-based compensation through recognition of the cost of employee services received in exchange for an award of equity instruments, which is measured based on the grant date fair value of the award that is ultimately expected to vest during the period. The stock-based compensation expenses are recognized over the period during which an employee is required to provide service in exchange for the award (the requisite service period, which in the Company’s case is the same as the vesting period). For awards subject to the achievement of performance metrics, stock-based compensation expense is recognized when it becomes probable that the performance conditions will be achieved.
	RECENT ACCOUNTING PRONOUNCEMENTS
	In May 2014, the Financial Accounting Standards Board (FASB)  issued Accounting Standards Update (ASU) No. 2014-09—“Revenue from Contracts with Customers” (Topic 606) which amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which an entity expects to be entitled in exchange for those goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract.  This accounting guidance is effective for the Company beginning in the first quarter of fiscal year 2018 using one of two prescribed retrospective methods.  Early adoption is not permitted.  The Company is evaluating the impact of the amended revenue recognition guidance on the Company’s consolidated financial statements.
	In July 2013, the FASB issued ASU No. 2013-11 “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists.” Under ASU 2013-11, an entity is required to present an unrecognized tax benefit, or a portion of an unrecognized tax benefit, in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward. If a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. ASU 2013-11 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The adoption of this guidance affects presentation only and, therefore, did not have a material impact on the Company's financial condition, results of operations or cash flows.
	Management has evaluated other recently issued accounting pronouncements and does not believe that any of these pronouncements will have a material impact on the Company’s consolidated financial statements.

Property_and_Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2014
Property Plant And Equipment [Abstract]	'
Property and Equipment	'
	(3) PROPERTY AND EQUIPMENT
	Property and equipment as of September 30, 2014 and December 31, 2013 consist of the following:
		September 30,			December 31,			Useful
		2014			2013			lives
		(UNAUDITED)
	Office furniture and equipment	$	1,752		$	2,073			3-7 years
	Rental inventory		1,342			2,142			5 years
	Vehicles		76			76			5 years
	Leasehold improvements		874			486			2-6 years
	Assembly equipment		125			171			7 years
			4,169			4,948
	Less accumulated depreciation		(2,336	)		(2,057	)
		$	1,833		$	2,891

Intangible_Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2014
Goodwill And Intangible Assets Disclosure [Abstract]	'
Intangible Assets	'
	(4) INTANGIBLE ASSETS
	Intangible assets as of September 30, 2014 and December 31, 2013, consist of software development costs of $345 and $325, respectively. Accumulated amortization was $203 and $147, respectively.

Earnings_Loss_Per_Share

Earnings (Loss) Per Share	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Earnings (Loss) Per Share	'
	(5) EARNINGS (LOSS) PER SHARE
	Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding and the number of dilutive potential common share equivalents during the period, calculated using the treasury-stock method.
	The calculation of basic and diluted loss per share for the three and nine months ended September, 2014 and 2013 is as follows:
		Three months ended					Nine months ended
		September 30,					September 30,
		2014		2013			2014			2013
	Basic:
	Net income (loss) applicable to common stockholders	$	258	$	(738	)	$	(6,724	)	$	(2,758	)
	Weighted average shares outstanding – basic		31,215,799		31,148,234			31,186,252			31,148,234
	Net loss per share – basic	$	0.01	$	(0.02	)	$	(0.22	)	$	(0.09	)
	Diluted:
	Net Income (loss) applicable to common stockholders	$	258	$	(738	)	$	(6,724	)	$	(2,758	)
	Weighted average shares outstanding – basic		31,215,799		31,148,234			31,186,252			31,148,234
	Dilutive securities	—		—			—			—
	Weighted average shares outstanding – diluted		31,215,799		31,148,234			31,186,252			31,148,234
	Net income (loss) per share – diluted	$	0.01	$	(0.02	)	$	(0.22	)	$	(0.09	)
	The effects of potential common stock equivalents, related to certain outstanding options for the three and nine months ended September 30, 2014 and 2013 were excluded from the computation of diluted net income (loss) per share as their inclusion would have an antidilutive effect.

StockBased_Compensation_Plans

Stock-Based Compensation Plans	9 Months Ended
	Sep. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stock-Based Compensation Plans	'
	(6) STOCK-BASED COMPENSATION PLANS
	The Company has reserved 3,000,000 shares of common stock for issuance under its 2005 Stock Option Plan (the “Option Plan”). Vesting provisions are determined by the Board of Directors. All stock options under the Option Plan expire no later than ten years from the date of grant.
	In the three months ended September 30, 2014 and 2013, the Company recorded compensation expense related to stock options of $18 and $29, respectively. Stock-based compensation recorded in the accompanying condensed consolidated statement of operations for the three months ended September 30, 2014 and 2013 included $2 and $2, respectively, in cost of goods sold and $16 and $27, respectively, in selling, general and administrative expenses.
	In the nine months ended September 30, 2014 and 2013, the Company recorded compensation expense related to stock options of $74 and $98, respectively. Stock-based compensation recorded in the accompanying condensed consolidated statement of operations for the nine months ended September 30, 2014 and 2013 included $6 and $9, respectively, in cost of goods sold and $68 and $89, respectively, in selling, general and administrative expenses.
	In the nine months ended September 30, 2014, the Company granted options to purchase up to 400,000 shares of common stock to employees at a weighted average exercise price of $0.25. The options have a ten year life and vest over four years.
	The Company used the Black Scholes option pricing model to determine the fair value of stock option grants, using the following assumptions during the three and nine months ended September 30, 2014:
		2014
	Weighted average expected term	6.25 years
	Weighted average volatility	113% to 121%
	Weighted average risk-free interest rate	1.4% to 1.7%
	Dividend yield	0%
	A summary of stock option activity under the Option Plan for the nine months ended September 30, 2014 is presented below:
		Shares			Weighted		Weighted		Aggregate
		Under			Average		Average		Intrinsic
		Option			Exercise		Remaining		Value
					Price		Contractual
							Life
	Outstanding at January 1, 2014		2,472,216		$	0.57
	Granted		400,000		$	0.25
	Exercised		—
	Forfeited		(1,146,697	)	$	0.42
	Outstanding at September 30, 2014		1,725,519		$	0.59		7.5 years	$	-
	Exercisable at September 30, 2014		608,917		$	1.06		4.9 years	$	-
	A summary of status of the Company’s non-vested share awards as of and for the nine months ended September 30, 2014 is presented below:
		Nonvested Shares			Weighted Average
		Under Option			Grant Date Fair Value
	Non-vested at January 1, 2014		1,663,593		$	0.29
	Granted		400,000		$	0.22
	Vested		(120,294	)	$	0.71
	Forfeited		(826,697	)	$	0.25
	Non-vested at September 30, 2014		1,116,602		$	0.29
	As of September 30, 2014, the Company had approximately $174 of unrecognized compensation expense related to stock options that will be recognized over a weighted average period of approximately 3.19 years.

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	(7) FAIR VALUE MEASUREMENTS
	The Company measures certain assets and liabilities pursuant to accounting guidance which establishes a three-tier fair value hierarchy and prioritizes the inputs used in measuring fair value. These tiers include:
	—	Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities.
	—	Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.
	—	Level 3: Unobservable inputs are used when little or no market data is available.
	The following table presents information about the Company’s financial assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2014, and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value:
		September 30,		Significant
		2014		Unobservable
				Inputs
				(Level 3)
	Liabilities:
	Contingent consideration	$	4	$	4
	The fair value of the contingent consideration was determined using a discounted cash flow model at the acquisition date and is revalued at each reporting date or more frequently if circumstances dictate based on changes in the discount periods and rates, changes in the timing and amount of the revenue estimates and changes in probability assumptions with respect to the likelihood of achieving the obligations. Contingent payments of $4 were made in April 2014 related to 2013.
	Changes in the fair value of these obligations are recorded as income or expense within the line item “Other income (expense)” in the Company’s consolidated statements of operations. Accretion expense related to the increase in the net present value of the contingent liabilities is also included in the line item “Other income (expense)” in the Company’s consolidated statements of operations. The fair value measurement is based on significant inputs not observable in the market, which are referred to as Level 3 inputs.
	Changes in the fair value of the Level 3 liabilities for the three and nine months ended September 30, 2014 were not significant.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	(8) INCOME TAXES
	The provision for income taxes is recorded at the end of each interim period based on the Company’s best estimate of its effective income tax rate expected to be applicable for the full fiscal year. The Company’s effective income tax rate was 0% for both the three and nine months ended September 30, 2014 and was approximately 37% for the corresponding 2013 periods. During the three and nine months ended September 30, 2014 the Company generated approximately $0 and $2,484, respectively, of deferred tax assets relating primarily to net operating loss carryforwards. However, as realization of these deferred tax assets is not more likely than not, a full valuation allowance was provided against the net deferred tax assets as of September 30, 2014. The Company paid income taxes of $0 and $2 during the three and nine months ended September 30, 2014, respectively, and received $674 of its income tax receivable of $893 during the nine month period.

Line_of_Credit

Line of Credit	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Line of Credit	'
	(9) LINE OF CREDIT
	The Company has an asset-backed revolving credit facility under a Loan and Security Agreement as amended, (the “Triumph Agreement”) with Triumph Healthcare Finance, a division of Triumph Community Bank. The Triumph Agreement contains certain customary restrictive and financial covenants for asset-backed credit facilities. As of September 30, 2014, the Company was not in compliance with the financial covenants under the Triumph Agreement. On July 14, 2014, the Company received notice from Triumph of an event of default under the Triumph Agreement. The notice relates to the Company’s default under the minimum debt service coverage ratio requirement for the quarter ended March 31, 2014 and certain other alleged defaults. The Lender notified the Company that it was exercising its default remedies under the Triumph Agreement, including, among others, accelerating the repayment of all outstanding obligations under the Triumph Agreement (outstanding principal and accrued interest) and collecting the Company’s bank deposits to apply towards the outstanding obligations. The Company and the Lender are negotiating the terms of an accelerated repayment of the amounts outstanding under the Triumph Agreement and the Lender has continued to make additional loans to the Company under the facility. However, no assurance can be given that the Lender will continue to make such additional loans or that the parties will agree on a repayment plan acceptable to the Company. If the Lender insists upon immediate repayment, the Company will be insolvent and may be forced to seek protection from creditors.   As of September 30, 2014, $4,541 was outstanding under the Triumph Agreement and zero was available for borrowing based on the default status and demand for accelerated payment. Borrowings under the Triumph Agreement bear interest at the default interest rate. As of September 30, 2014, the effective interest rate under the Triumph Agreement was 11.00% (6.75% interest rate plus 3% additional default interest rate and 1.25% fees). The Triumph Agreement requires monthly interest payments in arrears on the first date of each month. The Triumph Agreement will mature on December 19, 2014.

Concentrations

Concentrations	9 Months Ended
	Sep. 30, 2014
Risks And Uncertainties [Abstract]	'
Concentrations	'
	(10) CONCENTRATIONS
	The Company sourced approximately 21% and 34% of components for its electrotherapy products from one vendor during the nine months ended September 30, 2014 and 2013, respectively. Management believes that its relationships with suppliers are good; however, the Company has delayed and extended payments to many of its vendors for cash flow reasons, which has caused many of its vendors to require pre-payment for products or services. If the relationships were to be replaced, there may be a short-term disruption to operations, a period of time in which products may not be available and additional expenses may be incurred.
	The Company had receivables from a private health insurance carrier at September 30, 2014 and December 31, 2013 that made up approximately 5% and 7%, respectively, of the net accounts receivable balance.

Litigation

Litigation	9 Months Ended
	Sep. 30, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Litigation	'
	(11) LITIGATION
	From time to time, the Company may become party to litigation and other claims in the ordinary course of business. To the extent that such claims and litigation arise, management would provide for them if losses are determined to be both probable and estimable.
	The Company is currently not a party to any material pending legal proceedings.

Segment_Reporting

Segment Reporting	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Segment Reporting	'
	(12) SEGMENT REPORTING
	At September 30, 2014, the Company determined that it has one reporting segment, the Electrotherapy and Pain Management segment, which includes the ZMI TENS units and compound pain creams that accounted for 95% of total net revenue for the nine months ended September 30, 2014. The determination was made based on the fact that the products are marketed through the same sales representatives and to the same medical providers whether the provider writes a prescription for a TENS device or compound pain cream. As discussed in Note 1, during the second quarter ended June 30, 2014, the Company narrowed it focus on these products. The revenue generated from the sale of other products and services is not significant.
	Net revenue was primarily generated from sales in the United States.

Subsequent_Event

Subsequent Event	9 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Event	'
	(13) SUBSEQUENT EVENT
	On October 31, 2014, the Company entered into a Lease Termination Agreement (“LTA”) and new Lease Agreement (“LA”) with its landlord relating to the Company’s headquarters location in Lone Tree, Colorado, under which the Company will reduce the amount of space leased at its headquarters. The following is a summary of the key terms of the LTA:
	·	Monthly rental payments of $43 from September 1, 2014 through December 31, 2014;
	·	The Company vacates the unleased portion property on or before December 31, 2014;
	·	The existing lease will terminate as of December 31, 2014;
	·	The Company will surrender to the Landlord substantially all of the furniture and fixtures and leasehold improvements in the portion of the building being vacated at no cost to the landlord; and
	·	Effective upon termination of the existing lease, all amounts due to the landlord for deferred rent and any other charges will be forgiven.
	The following is a summary of the key terms of the new LA:
	·	The term of the LA shall be two years to commence on January 1, 2015 and to end, unless sooner terminated on December 31, 2016;
	·	Fixed rental payments of $49 per month; and
	·	The Company and landlord shall each have the right to terminate the lease at any time, without liability to the other, with six months prior written notice to the Company and three months written notice to the Landlord.
	At September 30, 2014, the estimated net book value of the furniture and fixtures that will be surrendered to the landlord was $56. In addition, upon vacating the property in the fourth quarter of 2014, the Company expects to write-off the net book value of its leasehold improvements which amounted to $549 at September 30, 2014. Also, included in the consolidated balance sheet at September 30, 2014 is a liability for deferred rent amounting to $2,845 which will be forgiven upon termination of the existing lease, which is expected to occur in the fourth quarter of 2014.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Principles of Consolidation	'
	PRINCIPLES OF CONSOLIDATION
	The accompanying unaudited condensed consolidated financial statements include the accounts of Zynex, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Noncontrolling Interest	'
	NONCONTROLLING INTEREST
	Noncontrolling interest in the equity of a subsidiary is accounted for and reported as stockholders’ (deficit) equity. Noncontrolling interest represents the 20% ownership in the Company’s majority-owned subsidiary, ZBC.
Use of Estimates	'
	USE OF ESTIMATES
	Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The most significant management estimates used in the preparation of the accompanying condensed consolidated financial statements are associated with the allowance for contractual adjustments and uncollectible accounts receivable, the reserve for obsolete and damaged inventory, stock-based compensation, valuation of long-lived assets, and income taxes.
Revenue Recognition and Allowances for Provider Discounts and Collectability	'
	REVENUE RECOGNITION, ALLOWANCE FOR CONTRACTUAL ADJUSTMENTS AND COLLECTIBILITY
	The Company recognizes revenue when each of the following four conditions are met: 1) a contract or sales arrangement exists, 2) products have been shipped and title has transferred, or rental services have been rendered, 3) the price of the products or services is fixed or determinable, and 4) collectability is reasonably assured. Accordingly, the Company recognizes revenue, both rental and sales, when products have been delivered to the patient and the patient’s insurance (if the patient has insurance) has been verified. For medical products that are sold from inventories consigned at clinic locations, the Company recognizes revenue when it receives notice that the product has been prescribed and delivered to the patient and the patient’s insurance coverage has been verified or preauthorization has been obtained from the insurance company, when required. Revenue from the rental of products is normally on a month-to-month basis and is recognized ratably over the products’ rental period. Revenue from sales to distributors is recognized when the Company ships its products, which fulfills its order and transfers title. Revenue is reported net, after adjustments for estimated insurance company or governmental agency (collectively “Third-party Payors”) reimbursement deductions. The deductions are known throughout the health care industry as “contractual adjustments” whereby the Third-party Payors unilaterally reduce the amount they reimburse for the Company’s products.
	A significant portion of the Company’s revenues are derived, and the related receivables are due, from Third-party Payors. The nature of these receivables within this industry has typically resulted in long collection cycles. The process of determining what products will be reimbursed by Third-party Payors and the amounts that they will reimburse is complex and depends on conditions and procedures that vary among providers and may change from time to time. The Company maintains an allowance for contractual adjustments and records additions to the allowance to account for the risk of nonpayment. Contractual adjustments result from reimbursements from Third-party Payors that are less than amounts claimed or where the amount claimed by the Company exceeds the Third-party Payors’ usual, customary and reasonable reimbursement rate. The Company determines the amount of the allowance, and adjusts it at the end of each reporting period, based on a number of factors, including historical rates of collection, the aging of the receivables, trends in the historical rates of collection and current relationships and experience with the Third-party Payors. If the rates of collection of past-due receivables recorded for previous fiscal periods changes, or if there is a trend in the rates of collection on those receivables, the Company may be required to change the rate at which it provides for additions to the allowance. A change in the rates of the Company’s collections can result from a number of factors, including experience and training of billing personnel, changes in the reimbursement policies or practices of Third-party Payors, or changes in industry rates of reimbursement. Accordingly, changes to the allowance for contractual adjustments, which are recorded in the income statement as a reduction of revenue, have historically fluctuated and may continue to fluctuate significantly from quarter to quarter.
	Due to the nature of the industry and the reimbursement environment in which the Company operates, estimates are required to record net revenues and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of third-party billing arrangements and the uncertainty of reimbursement amounts for certain products or services from payors or unanticipated requirements to refund payments previously received may result in adjustments to amounts originally recorded. Due to continuing changes in the health care industry and third-party reimbursement, as well as changes in our billing practices to increase cash collections, it is possible that management’s estimates could change in the near term, which could have an impact on our results of operations and cash flows. Any differences between estimated settlements and final determinations are reflected as an increase or a reduction to revenue in the period when such final determinations are known.
	The Company frequently receives refund requests from insurance providers relating to specific patients and dates of service. Billing and reimbursement disputes are very common in the Company’s industry. These requests are sometimes related to a limited number of patients or products; at other times, they include a significant number of refund claims in a single request. The Company reviews and evaluates these requests and determines if any refund request is appropriate. The Company also reviews these refund claims when it is rebilling or pursuing reimbursement from that insurance provider. The Company frequently has significant offsets against such refund requests, and sometimes amounts are due to the Company in excess of the amounts of refunds requested by the insurance providers. Therefore, at the time of receipt of such refund requests, the Company is generally unable to determine if a refund request is valid and should be accrued.
	As of September 30, 2014, the Company believes it has an adequate allowance for contractual adjustments relating to all known insurance disputes and refund requests. However, no assurances can be given with respect to such estimates of reimbursements and offsets or the ultimate outcome of any refund requests.
	In addition to the allowance for contractual adjustments, the Company records an allowance for uncollectible accounts receivable. Uncollectible accounts receivable are primarily a result of non-payment from patients who have been direct billed for co-payments or deductibles, lack of appropriate insurance coverage and disallowances of charges by Third-party Payors. If there is a change to a material insurance provider contract or policy, application by a provider, a decline in the economic condition of providers or a significant turnover of Company billing personnel resulting in diminished collection effectiveness, the estimate of the allowance for uncollectible accounts receivable may not be adequate and may result in an increase in the future. At September 30, 2014 and December 31, 2013, the allowance for uncollectible accounts receivable is $936 and $1,837, respectively.
	At September 30, 2014, the Company recorded a liability for deferred revenue in the amount of $109 which represents amounts paid by Third-party Payors for consumable supplies that were not shipped to patients as of September 30, 2014. This liability was reduced to zero in October 2014. There was no such liability at December 31, 2013.
Fair Value of Financial Instruments	'
	FAIR VALUE OF FINANCIAL INSTRUMENTS
	The Company’s financial instruments at September 30, 2014 include cash, accounts receivable and accounts payable, for which current carrying amounts approximate fair value due to their short-term nature. Financial instruments at September 30, 2014 also include the line of credit and notes payable, the carrying value of which approximates fair value because the interest rates on the outstanding borrowings are at rates that approximate market rates for borrowings with similar terms and average maturities.
Inventory	'
	INVENTORY
	Inventories, which primarily represent finished goods, are valued at the lower of cost (average) or market. In the second quarter of 2014, the Company narrowed its focus to the NexWave, InWave and NeuroMove electrotherapy products and building the sales representative group for its TENS and compound pain cream solutions.  As a result, the Company wrote-off all inventory unrelated to those specific product lines and recorded a charge to cost of revenue – write-off of noncore inventory in the amount of $2,005 during the nine month period ended September 30, 2014. Finished goods include products held at the Company’s headquarters and at different locations by health care providers or other parties for rental or sale to patients. Total (gross) inventories at September 30, 2014 included $2,506 of finished goods, $247 of parts, and $390 of supplies.
	The Company monitors inventory for turnover and obsolescence, and records losses for excess and obsolete inventory as appropriate. The Company provides reserves for estimated excess and obsolete inventories equal to the difference between the costs of inventories on hand and the estimated market value based upon assumptions about future demand. If future demand is less favorable than currently projected by management, additional inventory write-downs may be required. To fulfill orders faster, the Company places a large amount of its inventory with field sales representatives. This increases the sensitivity of these products to obsolescence reserve estimates. As this inventory is not in the Company’s possession, management maintains additional reserves for estimated shrinkage of these inventories based on the Company’s aging. At September 30, 2014, the Company had an allowance for obsolete and damaged inventory of approximately $660. The allowance for obsolete and damaged inventory was approximately $1,278 at December 31, 2013. The decrease from December 31, 2013 is due primarily to the write-off of noncore inventory discussed above. In addition, in the second quarter of 2014, the Company changed its method of estimation for determining allowances for obsolete and damaged inventory. The Company now estimates that finished units held for sale will be reserved beginning in year three and fully reserved after four years compared to five years previously. This change in estimate had the effect of increasing the allowances for obsolete and damaged inventory by approximately $414 at September 30, 2014 and increasing cost of revenue – sales by approximately $168 ($0.01 per share) and $414 ($0.02 per share) for the three and nine months ended September 30, 2014 respectively. The Company had $107 of open purchase commitments at September 30, 2014.
Property and Equipment	'
	PROPERTY AND EQUIPMENT
	Property and equipment are stated at cost. Products on rental contracts are placed in property and equipment and depreciated over their estimated useful life. The Company removes the cost and the related accumulated depreciation from the accounts of assets sold or retired, and the resulting gains or losses are included in the results of operations. Depreciation is computed using the straight-line method over the useful life of the asset. As rental inventory contributes directly to the revenue generating process, the Company classifies the depreciation of rental inventory in cost of revenue. As a result of the Company’s change in product focus discussed above, the Company wrote-off all rental inventory unrelated to those specific product lines and recorded a charge to cost of revenue – write-off of noncore inventory of $650 in the second quarter of 2014.
	Repairs and maintenance costs are charged to expense as incurred.
Intangible Assets	'
	INTANGIBLE ASSETS
	Intangible assets with estimable lives are amortized in a pattern consistent with the asset’s identifiable cash flows or using a straight- line method over their remaining estimated benefit periods if the pattern of cash flows is not estimable. The Company reviews the carrying value of intangible and other long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by comparison of their carrying amounts to the undiscounted cash flows that the asset or asset group is expected to generate. If the carrying amount of the assets exceeds the undiscounted cash flows the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Intangible assets primarily include capitalized software. The Company capitalizes software development costs incurred during the application development stage related to new software or major enhancements to the functionality of existing software that is developed solely to meet the entity’s internal operational needs and when no substantive plans exist or are being developed to market the software externally. Costs capitalized include external direct costs of materials and services and internal payroll and payroll-related costs. Any costs during the preliminary project stage or related to training or maintenance are expensed as incurred. Capitalization ceases when the software project is substantially complete and ready for its intended use. The capitalization and ongoing assessment of recoverability of development costs requires considerable judgment by management with respect to certain external factors, including, but not limited to, technological and economic feasibility, and estimated economic life.  When the projects are ready for their intended use, the Company amortizes such costs over their estimated useful lives of five years.
Stock-based Compensation	'
	STOCK-BASED COMPENSATION
	The Company accounts for stock-based compensation through recognition of the cost of employee services received in exchange for an award of equity instruments, which is measured based on the grant date fair value of the award that is ultimately expected to vest during the period. The stock-based compensation expenses are recognized over the period during which an employee is required to provide service in exchange for the award (the requisite service period, which in the Company’s case is the same as the vesting period). For awards subject to the achievement of performance metrics, stock-based compensation expense is recognized when it becomes probable that the performance conditions will be achieved.
Recent Accounting Pronouncements	'
	RECENT ACCOUNTING PRONOUNCEMENTS
	In May 2014, the Financial Accounting Standards Board (FASB)  issued Accounting Standards Update (ASU) No. 2014-09—“Revenue from Contracts with Customers” (Topic 606) which amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which an entity expects to be entitled in exchange for those goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract.  This accounting guidance is effective for the Company beginning in the first quarter of fiscal year 2018 using one of two prescribed retrospective methods.  Early adoption is not permitted.  The Company is evaluating the impact of the amended revenue recognition guidance on the Company’s consolidated financial statements.
	In July 2013, the FASB issued ASU No. 2013-11 “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists.” Under ASU 2013-11, an entity is required to present an unrecognized tax benefit, or a portion of an unrecognized tax benefit, in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward. If a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. ASU 2013-11 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The adoption of this guidance affects presentation only and, therefore, did not have a material impact on the Company's financial condition, results of operations or cash flows.
	Management has evaluated other recently issued accounting pronouncements and does not believe that any of these pronouncements will have a material impact on the Company’s consolidated financial statements.

Property_and_Equipment_Tables

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2014
Property Plant And Equipment [Abstract]	'
Property and Equipment	'
	Property and equipment as of September 30, 2014 and December 31, 2013 consist of the following:
		September 30,			December 31,			Useful
		2014			2013			lives
		(UNAUDITED)
	Office furniture and equipment	$	1,752		$	2,073			3-7 years
	Rental inventory		1,342			2,142			5 years
	Vehicles		76			76			5 years
	Leasehold improvements		874			486			2-6 years
	Assembly equipment		125			171			7 years
			4,169			4,948
	Less accumulated depreciation		(2,336	)		(2,057	)
		$	1,833		$	2,891

Earnings_Loss_Per_Share_Tables

Earnings (Loss) Per Share (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Calculation of Basic and Diluted Earnings Per Share	'
	The calculation of basic and diluted loss per share for the three and nine months ended September, 2014 and 2013 is as follows:
		Three months ended					Nine months ended
		September 30,					September 30,
		2014		2013			2014			2013
	Basic:
	Net income (loss) applicable to common stockholders	$	258	$	(738	)	$	(6,724	)	$	(2,758	)
	Weighted average shares outstanding – basic		31,215,799		31,148,234			31,186,252			31,148,234
	Net loss per share – basic	$	0.01	$	(0.02	)	$	(0.22	)	$	(0.09	)
	Diluted:
	Net Income (loss) applicable to common stockholders	$	258	$	(738	)	$	(6,724	)	$	(2,758	)
	Weighted average shares outstanding – basic		31,215,799		31,148,234			31,186,252			31,148,234
	Dilutive securities	—		—			—			—
	Weighted average shares outstanding – diluted		31,215,799		31,148,234			31,186,252			31,148,234
	Net income (loss) per share – diluted	$	0.01	$	(0.02	)	$	(0.22	)	$	(0.09	)

StockBased_Compensation_Plans_

Stock-Based Compensation Plans (Tables)	9 Months Ended
	Sep. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Fair Value of Stock Options Grants	'
	The Company used the Black Scholes option pricing model to determine the fair value of stock option grants, using the following assumptions during the three and nine months ended September 30, 2014:
		2014
	Weighted average expected term	6.25 years
	Weighted average volatility	113% to 121%
	Weighted average risk-free interest rate	1.4% to 1.7%
	Dividend yield	0%
Summary of Stock Option Activity Under the Option Plan	'
	A summary of stock option activity under the Option Plan for the nine months ended September 30, 2014 is presented below:
		Shares			Weighted		Weighted		Aggregate
		Under			Average		Average		Intrinsic
		Option			Exercise		Remaining		Value
					Price		Contractual
							Life
	Outstanding at January 1, 2014		2,472,216		$	0.57
	Granted		400,000		$	0.25
	Exercised		—
	Forfeited		(1,146,697	)	$	0.42
	Outstanding at September 30, 2014		1,725,519		$	0.59		7.5 years	$	-
	Exercisable at September 30, 2014		608,917		$	1.06		4.9 years	$	-
Summary of Status of the Company's Non-Vested Shares Under Option	'
	A summary of status of the Company’s non-vested share awards as of and for the nine months ended September 30, 2014 is presented below:
		Nonvested Shares			Weighted Average
		Under Option			Grant Date Fair Value
	Non-vested at January 1, 2014		1,663,593		$	0.29
	Granted		400,000		$	0.22
	Vested		(120,294	)	$	0.71
	Forfeited		(826,697	)	$	0.25
	Non-vested at September 30, 2014		1,116,602		$	0.29

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value of Assets and Liabilities on a Recurring Basis	'
	The following table presents information about the Company’s financial assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2014, and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value:
		September 30,		Significant
		2014		Unobservable
				Inputs
				(Level 3)
	Liabilities:
	Contingent consideration	$	4	$	4

Unaudited_Condensed_Consolidat1

Unaudited Condensed Consolidated Financial Statements and Managements' Plans (Details Textual) (USD $)	3 Months Ended			9 Months Ended		12 Months Ended	15 Months Ended	9 Months Ended		1 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Jun. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Oct. 31, 2014
								Current Lease Agreement	Revised from September 1, 2014 through December 31, 2014	Revised from September 1, 2014 through December 31, 2014
										Subsequent Event
Condensed Financial Statements Captions [Line Items]	'	'	'	'	'	'	'	'	'	'
Percentage of limited liability	'	'	'	80.00%	'	'	'	'	'	'
Net loss	$268	'	($749)	($6,734)	($2,786)	($7,340)	'	'	'	'
Line of credit current borrowing capacity	0	'	'	0	'	'	0	'	'	'
Line of credit	4,541	'	'	4,541	'	5,820	4,541	'	'	'
Operating expenses reduced by cutting annual employee costs through headcount reduction	'	'	'	'	'	'	7,000	'	'	'
Monthly base rental payments	'	'	'	129	'	'	'	'	'	'
Future monthly base rental payments	'	'	'	'	'	'	'	43	49	49
Lease term	'	'	'	'	'	'	'	'	'2 years	'2 years
Lease commencement date	'	'	'	'	'	'	'	'	1-Jan-15	1-Jan-15
Lease agreement description	'	'	'	'	'	'	'	'Under the terms of the Termination Agreement, among other things, the Company agreed to consolidate its operations into approximately one-third of the total square footage it occupied previously; monthly base rental payments were reduced from approximately $129 to $43 for the period from September 1, 2014 through December 31, 2014	'The terms of the new lease will take effect January 1, 2015. The terms of the new lease include, among other things, a term of two years, fixed monthly base rental payments of approximately $48,000 for the full term of the lease; and, the right for either party to terminate the lease without future liability with six months written notice.	'
Cost of revenue - write-off of noncore inventory	'	'	'	2,655	'	'	'	'	'	'
Writeoff of noncore inventory	'	'	'	2,005	'	'	'	'	'	'
Write-off rental units	'	$650	'	$650	'	'	'	'	'	'

Significant_Accounting_Policie2

Significant Accounting Policies (Details Textual) (USD $)	3 Months Ended			9 Months Ended			9 Months Ended	3 Months Ended	9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Jun. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Oct. 31, 2014
							Software development costs	Inventory Valuation and Obsolescence	Inventory Valuation and Obsolescence	Subsequent Event
Significant Accounting Policies [Abstract]	'	'	'	'	'	'	'	'	'	'
Equity and Noncontrolling interest	20.00%	'	'	20.00%	'	'	'	'	'	'
Allowance for uncollectible accounts receivable	$936	'	'	$936	'	$1,837	'	'	'	'
Deferred revenue	109	'	'	109	'	0	'	'	'	0
Writeoff of noncore inventory	'	'	'	2,005	'	'	'	'	'	'
Inventory finished goods	2,506	'	'	2,506	'	'	'	'	'	'
Inventory parts	247	'	'	247	'	'	'	'	'	'
Inventory supplies	390	'	'	390	'	'	'	'	'	'
Reserve for obsolete and damaged inventory	660	'	'	660	'	1,278	'	'	'	'
Increase in reserve for obsolete and damaged inventory	'	'	'	'The Company now estimates that finished units held for sale will be reserved beginning in year three and fully reserved after four years compared to five years previously.	'	'	'	'	'	'
Increase in reserve for obsolete and damaged inventory	414	'	'	414	'	'	'	'	'	'
Cost of revenue - sales	1,211	'	1,289	2,976	4,664	'	'	168	414	'
Increase in cost of revenue per share	'	'	'	'	'	'	'	$0.01	$0.02	'
Open purchase commitments	107	'	'	107	'	'	'	'	'	'
Estimated useful lives	'	'	'	'	'	'	'5 years	'	'	'
Write-off rental units	'	$650	'	$650	'	'	'	'	'	'

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Property Plant And Equipment [Line Items]	'	'
Property and Equipment, Gross	$4,169	$4,948
Less accumulated depreciation	-2,336	-2,057
Property and Equipment, Net	1,833	2,891
Office furniture and equipment	'	'
Property Plant And Equipment [Line Items]	'	'
Property and Equipment, Gross	1,752	2,073
Office furniture and equipment | Minimum	'	'
Property Plant And Equipment [Line Items]	'	'
Property and Equipment, Useful Life	'3 years	'
Office furniture and equipment | Maximum	'	'
Property Plant And Equipment [Line Items]	'	'
Property and Equipment, Useful Life	'7 years	'
Rental inventory	'	'
Property Plant And Equipment [Line Items]	'	'
Property and Equipment, Gross	1,342	2,142
Property and Equipment, Useful Life	'5 years	'
Vehicles	'	'
Property Plant And Equipment [Line Items]	'	'
Property and Equipment, Gross	76	76
Property and Equipment, Useful Life	'5 years	'
Leasehold improvements	'	'
Property Plant And Equipment [Line Items]	'	'
Property and Equipment, Gross	874	486
Leasehold improvements | Minimum	'	'
Property Plant And Equipment [Line Items]	'	'
Property and Equipment, Useful Life	'2 years	'
Leasehold improvements | Maximum	'	'
Property Plant And Equipment [Line Items]	'	'
Property and Equipment, Useful Life	'6 years	'
Assembly equipment	'	'
Property Plant And Equipment [Line Items]	'	'
Property and Equipment, Gross	$125	$171
Property and Equipment, Useful Life	'7 years	'

Intangible_Assets_Details_Text

Intangible Assets (Details Textual) (Software development costs, USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Software development costs	'	'
Finite Lived Intangible Assets [Line Items]	'	'
Intangible assets, gross	$345	$325
Accumulated amortization	$203	$147

Earnings_Loss_Per_Share_Detail

Earnings (Loss) Per Share (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Basic:	'	'	'	'
Net income (loss) applicable to common stockholders	$258	($738)	($6,724)	($2,758)
Weighted average shares outstanding – basic	31,215,799	31,148,234	31,186,252	31,148,234
Net loss per share – basic	$0.01	($0.02)	($0.22)	($0.09)
Diluted:	'	'	'	'
Net income (loss) applicable to common stockholders	$258	($738)	($6,724)	($2,758)
Weighted average shares outstanding – basic	31,215,799	31,148,234	31,186,252	31,148,234
Dilutive securities	0	0	0	0
Weighted average shares outstanding – diluted	31,215,799	31,148,234	31,186,252	31,148,234
Net income (loss) per share – diluted	$0.01	($0.02)	($0.22)	($0.09)

StockBased_Compensation_Plans_1

Stock-Based Compensation Plans (Details Textual) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Stock-based compensation plans [Abstract]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	3,000,000	'	3,000,000	'
Stock Options Under Option Plan Maximum Expiry Period	'	'	'10 years	'
Stock Based Compensation Plans (Additional Textual) [Abstract]	'	'	'	'
Employee stock-based compensation expense	$18	$29	$74	$98
Granted options to purchase of common stock	'	'	400,000	'
Granted options to purchase of common stock, weighted average exercise price	'	'	$0.25	'
Granted options expiration period	'	'	'10 years	'
Granted options vesting period	'	'	'4 years	'
Unrecognized compensation expense related to stock options	174	'	174	'
Weighted-average period of unrecognized compensation expense related to stock option	'	'	'3 years 2 months 9 days	'
Cost of Sales	'	'	'	'
Stock Based Compensation Plans (Additional Textual) [Abstract]	'	'	'	'
Employee stock-based compensation expense	2	2	6	9
Selling, General and Administrative Expenses	'	'	'	'
Stock Based Compensation Plans (Additional Textual) [Abstract]	'	'	'	'
Employee stock-based compensation expense	$16	$27	$68	$89

StockBased_Compensation_Plans_2

Stock-Based Compensation Plans (Details)	9 Months Ended
	Sep. 30, 2014
Fair value of stock option grants	'
Weighted average expected term	'6 years 3 months
Dividend yield	0.00%
Maximum	'
Fair value of stock option grants	'
Weighted average volatility	121.00%
Weighted average risk-free interest rate	1.70%
Minimum	'
Fair value of stock option grants	'
Weighted average volatility	113.00%
Weighted average risk-free interest rate	1.40%

StockBased_Compensation_Plans_3

Stock-Based Compensation Plans (Details 1) (USD $)	9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014
Summary of stock option activity under the option Plan	'
Shares under option outstanding beginning balance	2,472,216
Shares under option, granted	400,000
Shares under option, exercised	0
Shares under option, forfeited	-1,146,697
Shares under option outstanding ending balance	1,725,519
Shares under option, exercisable ending balance	608,917
Weighted average exercise price outstanding beginning balance	$0.57
Weighted average exercise price, granted	$0.25
Weighted average exercise price, exercised	'
Weighted average exercise price, forfeited	$0.42
Weighted average exercise price outstanding ending balance	$0.59
Weighted average exercise price, exercisable ending balance	$1.06
Outstanding, weighted average exercise remaining contractual life	'7 years 6 months
Exercisable, weighted average exercise remaining contractual life	'4 years 10 months 24 days
Outstanding aggregate intrinsic value	$0
Exercisable aggregate intrinsic value	$0

StockBased_Compensation_Plans_4

Stock-Based Compensation Plans (Details 2) (USD $)	9 Months Ended
	Sep. 30, 2014
Summary of status of the Company's non-vested share awards	'
Nonvested shares under option at January 1, 2014	1,663,593
Nonvested share under option, granted	400,000
Nonvested share under option, vested	-120,294
Nonvested share under option, forfeited	-826,697
Nonvested shares under option at September 30, 2014	1,116,602
Weighted average grant date fair value at January 1, 2014	$0.29
Weighted average grant date fair value, granted	$0.22
Weighted average grant date fair value, vested	$0.71
Weighted average grant date fair value, forfeited	$0.25
Weighted average grant date fair value at September 30, 2014	$0.29

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (Fair Value, Measurements, Recurring, USD $)	Sep. 30, 2014
In Thousands, unless otherwise specified
Liabilities:	'
Contingent consideration	$4
Fair Value, Inputs, Level 3	'
Liabilities:	'
Contingent consideration	$4

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details Textual) (USD $)	0 Months Ended
In Thousands, unless otherwise specified	Apr. 30, 2014
Fair Value Measurements [Abstract]	'
Contingent payments	$4

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'	'	'	'	'
Statutory rate	0.00%	37.00%	0.00%	37.00%	'
Deferred tax assets related to net operating loss carryforwards	$0	'	$2,484	'	'
Income taxes paid (including interest and penalties)	0	'	2	384	'
State tax refunds	'	'	674	'	'
Income tax receivable	$219	'	$219	'	$893

Line_of_Credit_Details_Textual

Line of Credit (Details Textual) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Line of Credit Facility [Abstract]	'	'
Outstanding amount on the Credit Agreement	$4,541	$5,820
Date of Maturity	19-Dec-14	'
Revolving Credit Facility	'	'
Line of Credit Facility [Abstract]	'	'
Outstanding amount on the Credit Agreement	4,541	'
Remaining amount available for borrowing	$0	'
Effective interest rate under the Credit Agreement	11.00%	'
Interest rate	6.75%	'
Additional default interest rate	3.00%	'
Fees include in effective interest rate under the credit agreement	1.25%	'

Concentrations_Details_Textual

Concentrations (Details Textual)	9 Months Ended			12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Dec. 31, 2013
	Electrotherapy products	Electrotherapy products	Net accounts receivable	Net accounts receivable
Concentration Risk [Line Items]	'	'	'	'
Concentration Risk, Percentage	21.00%	34.00%	5.00%	7.00%

Segment_Reporting_Details_Text

Segment Reporting (Details Textual)	9 Months Ended
	Sep. 30, 2014
	Segment
Segment Reporting Information [Line Items]	'
Number of reporting segments	1
Total net revenue | ZMI Tens units and compound pain creams	'
Segment Reporting Information [Line Items]	'
Concentration Risk, Percentage	95.00%

Subsequent_Event_Details_Textu

Subsequent Event (Details Textual) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
In Thousands, unless otherwise specified			Office furniture and equipment	Leasehold improvements	Revised from September 1, 2014 through December 31, 2014	Revised from September 1, 2014 through December 31, 2014	Current Lease Agreement
						Maximum
Subsequent Event [Line Items]	'	'	'	'	'	'	'
Lease Initiation Date	'	'	'	'	31-Oct-14	'	'
Future monthly base rental payments	'	'	'	'	$49	'	$43
Lease termination date	'	'	'	'	'	31-Dec-16	31-Dec-14
Lease commencement date	'	'	'	'	1-Jan-15	'	'
Lease term	'	'	'	'	'2 years	'	'
Lease agreement written notice to company, terms	'	'	'	'	'6 months	'	'
Lease aggrement written notice to landlord, terms	'	'	'	'	'3 months	'	'
Estimated net book value of furniture and fixtures	'	'	56	'	'	'	'
Expected writeoff net book value of leasehold improvements	'	'	'	549	'	'	'
Deferred rent	$2,845	$2,454	'	'	'	'	'